Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout

NCT06846515 is registered in ClinicalTrials.gov with Arthrosi Therapeutics as lead sponsor.

NCT NCT06846515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06846515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout
Lead sponsor
Arthrosi Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
March 11, 2025
Completion date
September 18, 2026
Enrollment
866 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, gouty, gout, gout chronic, hyperuricemia